Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00504701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Vascular cognitive impairment].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2022
Pirogov Russian National Research Medical University, Moscow, Russia.
Vascular cognitive impairment is considered the second most common cause of dementia after Alzheimer's disease. One of the most significant factors leading to vascular dementia is stroke, which increases the risk of developing dementia by about 2 times. Delayed-onset post-stroke dementia is mainly due to severe small vessel disease, recurrent stroke, or concomitant Alzheimer's disease.
View Article and Find Full Text PDFInhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease.
Front Aging Neurosci
October 2022
Department of Gastroenterology, The People's Hospital of Yichun City, Yichun, China.
Alzheimer's disease (AD) is the most common form of dementia and is ranked as the 6th leading cause of death in the US. The prevalence of AD and dementia is steadily increasing and expected cases in USA is 14.8 million by 2050.
View Article and Find Full Text PDFSesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection.
Pharmaceutics
April 2021
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
Nicergoline (NIC) is a semisynthetic ergot alkaloid derivative applied for treatment of dementia and other cerebrovascular disorders. The efficacy of sesame oil to slow and reverse the symptoms of neurodegenerative cognitive disorders has been proven. This work aimed to formulate and optimize sesame oil-based NIC-nanostructured lipid carriers (NIC-NLCs) for intranasal (IN) delivery with expected synergistic and augmented neuroprotective properties.
View Article and Find Full Text PDFFeatures and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
J Ethnopharmacol
April 2018
Phytotherapy Research Lab., Medicinal & Aromatic Plant Division, Regional Plant Resource Centre, Forest & Environment Department, Govt. of Odisha, Nayapalli, Bhubaneswar 751015, India.
Article Synopsis
- Alzheimer's disease (AD) is a complex neurodegenerative disorder that affects memory and cognitive functions, with existing FDA-approved treatments only providing symptomatic relief rather than a cure.
- Various traditional and ethnobotanical sources, including plants used in Indian, Chinese, and European medicine, show promise in developing new AD therapies, while the overexploitation of specific medicinal plants has inspired the creation of synthetic drugs like rivastigmine and new prodrugs.
- The article emphasizes the need for a shift from a "one-molecule-one-target" approach to a "combination-drugs-multi-targets" strategy that addresses the multiple underlying factors of AD, along with exploring various biological sources for potential therapeutic agents.
[The use of acetyl-L-carnitine in gerontological practice].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2019
Federal State Budgetary Scientific Institution 'Mental Health Research Center', Moscow, Russia.
An analysis of literature data on the acetyl-L-carnitine treatment in gerontological practice is performed. This review describes the range of biochemical activity and mechanism of action of the drug. The profile and specificity of acetyl-L-carnitine action and the possibility of combining nicergoline with other drugs is discussed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!